BaseSpace
Import Your Data
QuickView

FAQ

More QuickView FAQs

Back to top
Clear Search sequence regions
(e.g. Breast Cancer, Adipose tissue, Biofuel, Rapamycin, rs6983267, PBX1, cell-cell adhesion)
Bookmark Forward

QuickView for gp160 (gene)


Body Atlas

Most Correlated Tissues

  1. Ileum mucosa
  2. Kidney cortex
  3. Small intestine
  4. Kidney medulla
  5. Kidney
Explore Body Atlas Results

Disease Atlas

Most Correlated Diseases

  1. 11p partial monosomy syndrome
  2. Disorder of iron metabolism
  3. Injury of integument
  4. Deficiency state
  5. Barrett's esophagus
Explore Disease Atlas Results

Pharmaco Atlas

Most Correlated Compounds

  1. iopromide
  2. Foscarnet
  3. TACSTD1 protein, human
  4. naphthalene
  5. ADP-ribosylating binary toxin, Clostridium difficile
Explore Pharmaco Atlas Results

Knockdown Atlas

Most Correlated Gene Perturbations

  1. SV40_Large_T_and_small_t_Ag_common-S
  2. LRPPRC
  3. PRKDC
  4. CDX1
  5. VAT1
Explore Knockdown Atlas Results

Curated Studies

Most Correlated Studies

Loading...
Explore Curated Studies Results

Literature

Most Relevant Literature

  1. Uncovering the role of TET2-mediated ENPEP activation in trophoblast cell fate determination.
  2. Aminopeptidase A (ENPEP) gene polymorphisms and preeclampsia: Descriptive analysis.
  3. Bioinformatic characterization of ENPEP, the gene encoding a potential cofactor for SARS-CoV-2 infec…
  4. Long-range regulatory interactions at the 4q25 atrial fibrillation risk locus involve PITX2c and ENP…
  5. Iron deficiency downregulates ENPEP to promote angiogenesis in liver tumors.
Explore Literature Results

Clinical Trials

Most Relevant Clinical Trials

  1. A Clinical Trial to Evaluate the Safety and Immunogenicity of CH505M5 N197D mRNA-gp160 Followed by C…
  2. A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope …
  3. A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope …
  4. Active Immunization of Asymptomatic, HIV-Infected Individuals With Recombinant GP160 HIV-1 Antigen: …
  5. A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and…
Explore Clinical Trials Results
  • Copyright © 2024 Illumina Inc. All rights reserved.